Vaxcyte Inc
Abierto
SectorSanidad
48.76 2.98
Resumen
Variación precio
24h
Mínimo
47.08
Máximo
48.88
Ingresos | -74M -321M |
|---|---|
BPA | -2.3 |
Empleados | 507 |
EBITDA | -105M -340M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +144.42% upside |
Próximas Ganancias | 4 ago 2026 |
|---|
Capitalización Mercado | -1.6B 6.8B |
|---|---|
Apertura anterior | 45.78 |
Cierre anterior | 48.76 |
Noticias sobre sentimiento de mercado
By Acuity
40%
60%
110 / 342 Clasificación en Healthcare
Vaxcyte Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.